Orkambi is one of a new class of treatments which tackles the underlying cause of cystic fibrosis. But with a UK list price of £104,000 the NHS has refused to fund it on cost effectiveness grounds.

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England. Leiden said that he is to ...